Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin
Highlight
– In the randomized OCEAN trial (n=1284), rivaroxaban (15 mg daily) did not significantly reduce a composite of stroke, systemic embolism, or new covert embolic stroke on MRI compared with aspirin over 3 years.
– Event rates were low in both arms (0.31 vs 0.66 events per 100 patient‑years), producing wide confidence intervals and limited statistical power for modest differences.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.